

Grifols successfully closes the issuance of additional EUR 300 million secured notes

- *This amount is in addition to the EUR 1 billion private placement completed on April 30, 2024.*
- *This increase is issued under the same economic terms: purchase price of 98.50% of the principal amount of the notes, annual coupon of 7.5% and maturity in May 2030.*
- *Grifols has the necessary resources to meet all its debt maturities in 2025.*

Barcelona (Spain), June 4, 2024 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced the increase by EUR 300 million of its private offering of EUR 1 billion of senior secured notes, closed on April 30, 2024, with the same economic terms: 7.5% annual coupon, due May 2030, and a purchase price of 98.50% of the principal amount of the notes. These notes benefit from the same guarantees and security interest.

Including this increase, Grifols' total issuance has reached EUR 1,300 million.

The proceeds have been received today and will be used to repay part of the revolving loans.

The EUR 1 billion previously issued and paid were used to redeem the Senior Unsecured Notes due May 2025.

This EUR 300 million increase and the successful closing of the previous EUR 1,000 million bond issue, both under the same conditions, demonstrate the confidence of the financial markets in Grifols' solid business and allow the company to strengthen its long-term financial framework.

Grifols has appointed Osborne Clarke and Proskauer Rose LLP as legal advisors. Bank of America and BNP Paribas have acted as placement agents to the Company.

The notes were sold in a private placement to qualified institutional buyers in reliance on section 4(a)(2) of the US Securities Act of 1933, as amended and to non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act.

GRIFOLS

INVESTORS:

Grifols Investors Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com / Tel. +34 93 571 00 02

Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – +34 91 311 92 90

Raquel Lumbreras (M. +34 659 572 185)

Raquel_lumbreras@duomocomunicacion.com

Borja Gómez (M. +34 650 402 225)

Borja_gomez@duomocomunicacion.com

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2023, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information about Grifols, please visit www.grifols.com



LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe securities in accordance with the provisions of the following Spanish legislation: Law 6/2023, of 17 March, of the Securities Markets and of Investment Services (*Ley 6/2023, de 17 de marzo, de los Mercados de Valores y de los Servicios de Inversión*), and any regulations developing this legislation. This communication does not constitute an offer to sell or the solicitation of an offer to buy the securities nor shall there be any offer, solicitation or sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws, and may not be offered or sold in the United States absent registration or pursuant to an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.